Roche Holding AG
ROP
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
E: investor.relations@roche.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
personal-finance
The US dollar looks overvalued. Should individual investors care?
Some things are a lot more important to professional investors than everybody else.
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,961.30 | 46.50 | 0.52% |
| CAC 40 | 8,326.62 | 73.96 | 0.90% |
| DAX 40 | 25,118.27 | 220.82 | 0.89% |
| Dow JONES (US) | 52,539.66 | 191.27 | 0.37% |
| FTSE 100 | 10,472.45 | 16.59 | -0.16% |
| HKSE | 24,030.18 | 169.28 | -0.70% |
| NASDAQ | 26,190.06 | 319.41 | 1.23% |
| Nikkei 225 | 67,743.85 | 924.80 | 1.38% |
| NZX 50 Index | 13,785.67 | 120.49 | 0.88% |
| S&P 500 | 7,543.82 | 61.11 | 0.82% |
| S&P/ASX 200 | 8,762.50 | 44.40 | 0.51% |
| SSE Composite Index | 4,036.59 | 65.71 | 1.65% |